Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The HIV-1 envelope glycoprotein gp41 N-terminal heptad repeat (NHR) deep pocket is a highly conserved hydrophobic cavity essential for the viral entry process (Chan et al., 1997; PMID: 9160751). During HIV-1 infection, the gp41 subunit mediates the fusion between the viral envelope and the host cell plasma membrane. This process involves a dramatic conformational change where three NHR helices form a trimeric coiled-coil, creating three longitudinal grooves that each contain a deep pocket (Liu et al., 2002; PMID: 11752710). The C-terminal heptad repeat (CHR) region of gp41 then folds back into these grooves, with its pocket-binding domain (PBD) inserting into the NHR deep pocket to form a stable six-helix bundle (6-HB). This 6-HB formation brings the viral and cellular membranes into close proximity, facilitating fusion. Because the NHR deep pocket is critical for 6-HB stability and is highly conserved across diverse HIV-1 strains, it serves as a primary target for fusion inhibitors (He et al., 2008; PMID: 18234671). Therapeutic agents, including second-generation peptides like Albuvirtide and various small-molecule inhibitors, are designed to occupy this pocket, thereby preventing the NHR-CHR interaction and blocking viral entry (Zhang et al., 2016; PMID: 27010161).
Inhibition of six-helix bundle (6-HB) formation by competitively binding to the NHR deep pocket, preventing the interaction between the NHR and CHR regions of gp41.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HIV-1 envelope glycoprotein gp41 N-terminal heptad repeat pocket (gp41 NHR pocket).